Tag: big pharma

“A Recurring Fountain Of Revenue”: FDA Exec Admits Biden Planning Annual Jabs, Including Toddlers

Food and Drug Administration (FDA) Executive Officer Christopher Cole was caught on undercover camera by Project Veritas, where he revealed that his agency plans to announce that annual Covid-19 vaccinations will become official policy.

As Project Veritas reports (emphasis ours):

Cole is an Executive Officer heading up the agency’s Countermeasures Initiatives, which plays a critical role in ensuring that drugs, vaccines, and other measures to counter infectious diseases and viruses are safe. He made the revelations on a hidden camera to an undercover Project Veritas reporter.

Cole indicates that annual COVID-19 shots isn’t probable — but certain. When pushed on how he knows an annual shot will become policy, Cole states, “Just from everything I’ve heard, they [FDA] are not going to not approve it.”

The footage, which is part one of a two-part series on the FDA, also contains soundbites from Cole about the financial incentives pharmaceutical companies like Pfizer have to get the vaccine approved for annual usage.

“It’ll be recurring fountain of revenue,” Cole said in the hidden camera footage. “It might not be that much initially, but it’ll recurring — if they can — if they can get every person required at an annual vaccine, that is a recurring return of money going into their company.”

Perhaps the most explosive part of the footage is the moment where Cole brazenly talks about the impact that an Emergency Use Authorization has on overcoming the regulatory concerns of mandating vaccines on children.

“They’re all approved under an emergency just because it’s not as impactful as some of the other approvals,” Cole said when asked if he thought there was “really an emergency for kids.”

Keep reading

Senator Who Took Donations From Big Pharma Blocks Vote on Bill to Lower Drug Prices

Republican Sen. Mike Crapo of Idaho blocked Sen. Bernie Sanders’ attempt Wednesday to force a vote on legislation that would slash prescription drug prices, thwarting the Vermont senator’s effort to fast-track the new bill as the pharmaceutical industry rushes to hike costs in the new year.

Sanders, chair of the Senate Budget Committee, requested unanimous consent to proceed to debate and a vote on the Cutting Medicare Prescription Drug Prices in Half Act, a measure he introduced earlier Wednesday alongside Sen. Amy Klobuchar (D-Minn.).

If passed, the bill would bring the prices of drugs covered by Medicare into line with what the Department of Veterans Affairs (VA) or the Federal Supply Schedule pay for the same medications.

According to a 2017 Government Accountability Office study, the VA “paid an average of 54% less per unit than Medicare” for a sample of hundreds of brand-name and generic drugs.

But Crapo — a major recipient of pharmaceutical and insurance industry donations — objected to Sanders’ request to advance the legislation, claiming it would usher in “more bureaucracy.”

Keep reading